In the case of loperamide, my guess is that it would indeed increase central activity; probably not much by itself but perhaps significantly when co administered with a p-GP inhibiter.
Correct me if I'm mistaken, my understanding if loperamide was that a little (yet some) crossed the BBB and was then rapidly removed by p-GP, the two limitations coming together to severely limit it's central affects. If loperamide crossed the BBB just fine and p-GP was either the sole or major issue then wouldn't one expect even fairly weak p-GP inhibitors (e.g. quinine) to radically increase the central mu effects? I've bioassayed loperamide with various p-GP inhibitors, fairly extensively with quinine in fact (lop' dose of 36 mg in all trials - lop' alone begins to exhibit central affects in me when the 30 mg line is crossed). Five separate assays over a 2 month period, all performed in the same location at the same time of day and without any other xenobiotics other than nicotine in my system. Assay 1: ~20 mg quinine, a2: ~70 mg, a3: ~250 mg, a4: 650 mg, a5: 1300 mg.
Possible increased central effects were felt in a1 and a2 but these were too mild to grant any certainty. Definite increases were felt in a3, 4 and 5. A3 led to a more-or-less full, if somewhat atypical opioid high that lacked strong euphoria and pin prick pupils but little else. A4 produced a significantly increased 'high' with a small amount of euphoria at times and slightly constricted pupils, a5 provided further pupil constriction but little else. (No nodding, no real euphoria, pupils small but not pinned.
While this assay proved jack, it does illustrate that p-GP inhibition does increase the central opioid effects of loperamide. However, if the removal of lop via p-GP was the main factor in making it an infamously weak central agonist then (given both lop's binding affinity for mu and it's comparative GI opioid effects at 36 mg dosages) you would expect the increase in central effects from a2 through a5 to be much greater, no?
Just to note I have a moderate tolerance to opiates which, over the 2 months these assays took place in, increased ever so slightly. No other loperamide was taken during the 2 months. My general loperamide use includes ~7 additional 'assays' of central effects spread out across a two year period, the very occasional use of loperamide as a relief for food poisoning etc ( <12 mg) and perhaps 10 occasions to help during morphine withdrawal (<16 mg).
Just my two pence...